Sharemaestro Newsreel

XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS

XBiotech (NASDAQ:XBIT) reported a quarterly loss of $0.22 per share, significantly missing analysts' consensus estimate of a $0.03 profit by $0.25. Following the announcement, XBIT shares fell by $0.13 to $2.33, nearing its 52-week low, and the company's market capitalization is approximately $71 million. …

Veru 3Q Loss $6.99M >VERU

This article reports that Veru (VERU) experienced a third-quarter loss of $6.99 million. The brief financial update indicates the company's performance for the recent fiscal period.

Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA?

Vera Therapeutics (VERA) received accelerated FDA approval for TRUTAKNA for IgA nephropathy, but its share price has fallen recently despite strong long-term returns. The company is currently loss-making and trades at a P/B ratio of 5.4x, which is below peers but above the broader …

Form 8K EDESA BIOTECH For: 13 August By Investing.com

This article reports that EDESA BIOTECH filed a Form 8K on August 13th, as tracked by Investing.com. The filing details are not provided within the article itself, but it highlights the company EDSA with a stock performance of +2.45%. The piece is primarily a …

Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?

Despite a recent 44.2% surge in Moderna's stock price, StockStory advises against investing in the company due to declining revenue and EPS over the last five years, and a negative free cash flow margin. The analysis suggests Moderna is a low-quality business, with the …

Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com

This article announces the filing of a Form 8K by Tempest Therapeutics Inc. on August 13. The brief notice from Investing.com indicates that the filing is a public record from the company. The article does not provide specific details about the content of the …

Renaissance Technologies (CORT) discloses 4.90% beneficial stake in Corcept Therapeutics

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 4.90% in Corcept Therapeutics Inc., amounting to 5,261,628 shares of common stock. This Schedule 13G/A filing indicates that Renaissance Technologies holds sole voting and dispositive power over these shares. Certain …

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Investor Relations - Stefanie Perna-NacarPresident and Chief Executive Officer - Jennifer BuellHead of Development - Terese HammondPrincipal Financial Officer - Melissa Orilall TAKEAWAYS Cash and Cash Equivalents -- …

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (CEO, President & Director Howard W. Robin). “With …

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

MediciNova (MNOV) reported a Q2 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.06 loss and improving from a $0.07 loss a year ago. The company also exceeded revenue estimates, posting $0.46 million against a $0.15 million consensus, though its …

Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe sold 12,700 shares of the company's stock for approximately $67,183. The sale occurred on August 12th when shares were trading at $5.29. Following the transaction, WVE shares fell to $5.20, near their 12-month low, and the company …

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

WAVE Life Sciences (NASDAQ:WVE) Director Heidi Wagner sold 7,000 shares of the company's stock for $42,070, reducing her position by 13.48%. The sale occurred amidst weak trading and quarterly results, with WVE shares near their 52-week low and the company reporting a loss and …

Parabilis Medicines (PBLS) Earnings Date and Reports 2026

Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test

Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, causing its stock price to drop significantly. Despite a current "undervalued" narrative with a fair value of $434.72 against its $227.12 close, …

Barclays Maintains Forte Biosciences(FBRX.US) With Hold Rating, Maintains Target Price $77

Barclays has reiterated its 'Hold' rating on Forte Biosciences (FBRX.US) and maintained its target price at $77. This indicates that the financial institution sees the stock performing in line with the broader market and expects its value to remain stable at the specified price …

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

Levi & Korsinsky has announced an investigation into Ardelyx (ARDX) following a significant 17.86% stock drop on August 7, 2026. This decline occurred after the company reported second-quarter 2026 product revenue and earnings per share that were below consensus estimates, and subsequently lowered its …

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position

Farallon Capital Management and its affiliated funds have disclosed a beneficial ownership of 10,282,210 shares of Beam Therapeutics (BEAM) common stock, representing 9.99% of the outstanding class. This position includes directly held shares and common stock purchase warrants, with exercisability capped at 9.99% due …

PTC takes a chance on Sangamo’s Fabry disease gene therapy

PTC Therapeutics has acquired an experimental gene therapy for Fabry disease, ST-920, from the bankrupt Sangamo Therapeutics for up to $211 million. Analysts view this as a risky but potentially high-reward move, as the treatment is nearing FDA approval and could offer a superior …

Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says

RBC Capital Markets highlighted that Definium Therapeutics' DT120 data from a Phase 2 proof-of-concept study, though not statistically significant, provides valuable insights into the drug's mechanisms and biomarkers. The firm believes this information significantly de-risks future trials, particularly the upcoming Phase 2b study which …

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer - Claude MaraouiChief Financial Officer - Joseph BeneschChief Operating Officer and General Counsel - Ramsey AlloushSenior Director of Corporate Operations - Jaclyn …

CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects.

CG Oncology's experimental drug cretositimogene grenadenorepvec (cret) has shown promising results in treating non-muscle invasive bladder cancer (NMIBC), achieving a 75% complete response rate and demonstrating a best-in-class safety profile with no severe adverse events. The company plans to submit a Biologics License Application …

Why Absci (ABSI) Is Up 14.0% After Positive Early ABS-201 Hair Loss Data And Endometriosis Plans

Absci Corporation's stock (ABSI) rose 14.0% after reporting positive interim Phase 1 results for ABS-201, a drug targeting pattern hair loss, showing favorable safety and tolerability. The company also announced plans to advance ABS-201 to Phase 2 testing for endometriosis in late 2026. This …

Capricor Therapeutics Faces Securities Lawsuit

Capricor Therapeutics (NASDAQ: CAPR) is facing a federal securities class action lawsuit alleging that the company made misleading statements regarding the regulatory prospects of its investigational cell therapy, deramiocel, for Duchenne muscular dystrophy. The lawsuit centers on alleged undisclosed changes to statistical analysis plans …

Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) has announced the pricing of an underwritten public offering of 23 million shares of common stock at $3.50 per share, aiming to raise approximately $80.5 million in gross proceeds. The offering is expected to close on August 17, 2026, with …

Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History

Atrium Therapeutics, Inc. (RNA), formerly Prosensa Holding B.V. Ordinary Shares, is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. The company's stock is currently trading at $12.84, with a slight increase after hours. Analysts maintain a "Buy" rating with a target price …

Form 8K Parabilis Medicines For: 13 August By Investing.com

The article is a brief financial news item from Investing.com, reporting on a Form 8K filing by Parabilis Medicines for August 13th. It provides no further details beyond stating the filing occurred on that date.

Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000

Parabilis Medicines, Inc. (PBLS) reported its Q2 revenue as $148,000. The company, a clinical-stage biopharmaceutical firm, focuses on developing transformative medicines for "undruggable" protein targets using its proprietary Helicon platform. Analysts currently have a "BUY" consensus for PBLS with an average target price of …

Nektar Therapeutics Q2 Earnings Call Highlights

CG Oncology Stock: Circling Back After Huge Rally (NASDAQ:CGON)

MediciNova (NASDAQ:MNOV) Announces Quarterly Earnings Results

MediciNova (NASDAQ:MNOV) exceeded quarterly earnings expectations, reporting a loss of $0.05 per share against an estimated $0.06 loss, and revenues of $0.46 million, significantly above the $0.07 million forecast. Despite the positive earnings surprise, the company experienced a slight dip in share price to …

MeiraGTx (NASDAQ:MGTX) Releases Quarterly Earnings Results, Beats Expectations By $2.17 EPS

Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter

Earnings Call Insights: Daré Bioscience (DARE) Q2 2026 MANAGEMENT VIEW * "In June, we launched Flora Sync LF5, the first product in our DARE to RESTORE line." (CEO, President, Principal Financial Officer, Secretary & Director Sabrina Johnson) * "At the same time, we continued …

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

The Rosen Law Firm has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made materially false and misleading statements regarding changes …

Cue Biopharma, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Cue Biopharma, Inc. (CUE) on August 14, 2026. The filing indicates a proposed sale of 8,829 shares of common stock with an aggregate market value of $266,106.06, acquired through Restricted Stock Units vesting under …

Richard Griffiths (SLN) reports 14.39M-share beneficial stake in Silence Therapeutics

Richard Griffiths has updated his beneficial ownership in Silence Therapeutics plc, reporting a 7.97% stake, or 14,391,498 ordinary shares. This amendment (Amendment No. 11) reflects significant dilution due to an increase in the issuer's share capital and includes the sale of 5,484,320 ADSs by …